TL;DR
Intranasal drug delivery represents a rapidly evolving and promising platform for targeted CNS therapeutics, offering a non-invasive approach with improved patient compliance and enhanced brain targeting, with particular emphasis on emerging technologies designed to improve CNS targeting and therapeutic efficacy.
Overall, nanocarrier-assisted nose-to-brain drug delivery represents a transformative platform for the management of central nervous system disorders and has the potential to overcome the limitations of conventional drug delivery systems and improve therapeutic outcomes for a wide range of neurological diseases.
Multimodal strategies integrating RMT, stimuli-responsive carriers, and CRISPRbased gene delivery may collectively overcome the translational gap that single-platform approaches have consistently failed to bridge.
Diseases of the central nervous system (CNS) and brain tumours are leading causes of death and disability globally. Drug delivery for CNS illnesses is highly difficult because of the blood-brain barrier (BBB). Medications can be delivered to the central nervous system (CNS) via nano-delivery systems, which can also enh...
NeuroAIDS refers to the spectrum of neuropsychiatric complications observed in approximately 30–50% of HIV/AIDS patients. Although the advent of antiretroviral therapy has reduced the severity of AIDS, mild cognitive deficits persist in nearly half of treated patients, highlighting limitations in central nervous system...
Abstract Efficient drug delivery to the central nervous system (CNS) remains a major challenge because the blood-brain barrier (BBB) restricts penetration of most drugs. In this review, we summarize key principles of a unique liposome- and extracellular vesicles (EV)-based drug delivery systems for CNS, highlighting th...
Recent advances in intranasal delivery position intranasal delivery as a versatile but evolving platform for next generation interventions in NDDs.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
